European Agency official associates AstraZeneca vaccine with cases of thrombosis – Observer

European Agency official associates AstraZeneca vaccine with cases of thrombosis – Observer
European Agency official associates AstraZeneca vaccine with cases of thrombosis – Observer

AstraZeneca. EMA official says there is an association with clots. There are more cases of cerebral thrombosis in younger people

The European Medicines Agency (EMA) Health Threats and Vaccines Strategy coordinator, Marco Cavaleri, said that there is an association between the AstraZeneca vaccine and blood clot formation, although it is not known how, according to the interview. published in the Italian newspaper Il Messagero

In my opinion, we can now say that it is clear that there is an association with the vaccine. What causes this reaction, however, we still don’t know ”, said Marco Cavaleri. “In short: in the next few hours we will say that this connection exists, but we still have to understand how it happens.”

Marco Cavaleri also explained that they seek to obtain “a clear picture of what is happening, to define precisely this syndrome induced by vaccination”. And that, among those vaccinated, there are more cases of cerebral thrombosis in younger people than one would expect. This will have to be said, ”he said.

The EMA is meeting this week to assess the relationship between the administration of the AstraZeneca vaccine and the rare thromboembolic events reported in several countries, including blood clots. The agency is expected to comment on the matter on Thursday.

It is hoped that EMA will recommend age-related limitations on the use of the AstraZeneca vaccine – as, by the way, is being done in several countries -, said Italian Vice Minister of Health Pierpaolo Sileri, quoted by the news agency Italian ANSA.

But Marco Cavaleri said, in the interview with Il Messagero: “This week we will start to give some preliminary indications, but we will hardly be able to indicate age limits as the various countries have done”. What is clear to the expert is that the product information will be updated to contain that these events could be potential side effects of the vaccine.

AstraZeneca. Fewer events with blood clots, but more deadly. EMA continues to investigate

The EMA had previously reported that, based on the cases analyzed, no specific risk factors associated with age, gender or clinical history of clotting had been found, but that the investigation would continue.

The Italian Medicines Agency will meet, this Tuesday, with the Italian Ministry of Health to decide whether changes will be made to the indications for using the AstraZeneca vaccine in Italy as well, but, before a final decision, the Italian authorities will wait by the EMA’s opinion.

“It is possible that, as a precaution, the European Medicines Agency indicates that for a certain category it is better not to use the AstraZeneca vaccine against Covid-19,” said the deputy minister of Health, who added that the benefits continue to outweigh the risks.

Get the latest news delivered to your inbox

Follow us on social media networks

PREV “Brazil has not yet reached rock bottom”, says doctor
NEXT SP City Hall suspends vaccination against Covid-19 at drive-thru posts starting this Tuesday | Sao Paulo